GALENICA N/ CH0360674466 /
2024-04-19 3:16:09 PM | Chg. +0.05 | Volume | Bid3:16:39 PM | Ask3:16:39 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
69.90CHF | +0.07% | 19,425 Turnover: 1.36 mill. |
69.75Bid Size: 317 | 69.85Ask Size: 174 | 3.5 bill.CHF | 3.15% | 12.23 |
GlobeNewswire
2023-09-18
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
GlobeNewswire
2021-11-17
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
GlobeNewswire
2021-08-19
Biofrontera reports financial results for the six months ended June 30, 2021
GlobeNewswire
2020-12-07
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz®...
GlobeNewswire
2019-07-11
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer...
GlobeNewswire
2019-06-18
Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance O...
GlobeNewswire
2018-05-23
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensin...
GlobeNewswire
2018-05-23
VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE...
GlobeNewswire
2018-05-08
Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa®...
GlobeNewswire
2018-04-16
Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
GlobeNewswire
2018-04-11
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at t...
GlobeNewswire
2018-03-27
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN